Abstract

FORMULATION AND EVALUATION OF TARGETED TABLET FORMULATION OF MELOXICAM FOR TREATMENT OF COLORECTAL CANCER

Fathima Musthafa*, Dr. Ibrahim Afsal V. T., Archana S., Fathima P. M., Ayisha Shafrin and Syamprasad P. S.

.

Abstract

Meloxicam is a preferential COX 2 inhibitor and a good chemopreventive agent and is used to prevent colorectal cancer. It’s local targeted action on colon makes the treatment more effective. So the aim of this study is to formulate and evaluate a targeted tablet formulation of meloxicam to achieve a site specific and instant delivery in the colon to effectively treat colorectal cancer. Meloxicam is poorly soluble acidic drug and has pH dependent solubility. Hence it is coated by buffering agents to obtain a pH independent drug release. core tablet is prepared by direct compression and coated by polymeric solution via pan coating method. The tablet contains 2% croscarmelose and 4% crospovidone as disintegrants shows instant drug release when reached colon. The drug content was found to be 96.9% which is within the USP standards. This study confirms that meloxicam targeted tablet formulation produce a targeted dug delivery and can be used as a potential treatment for colorectal cancer.

Keywords: Meloxicam, COX 2 inhibitor, colorectal cancer, targeted drug delivery.